Carlo Patrono

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5481163/publications.pdf

Version: 2024-02-01

322 papers	50,592 citations	3515 90 h-index	1489 219 g-index
333 all docs	333 docs citations	333 times ranked	39686 citing authors

#	Article	IF	Citations
1	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
2	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
3	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, The, 2009, 373, 1849-1860.	6.3	3,100
4	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
5	Platelet Activation and Atherothrombosis. New England Journal of Medicine, 2007, 357, 2482-2494.	13.9	1,831
6	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
7	The Coxibs, Selective Inhibitors of Cyclooxygenase-2. New England Journal of Medicine, 2001, 345, 433-442.	13.9	1,438
8	Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. Journal of the National Cancer Institute, 2002, 94, 252-266.	3.0	1,300
9	Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ: British Medical Journal, 2006, 332, 1302-1308.	2.4	1,204
10	Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine, 2005, 353, 2373-2383.	13.9	1,053
11	Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. New England Journal of Medicine, 2004, 350, 114-124.	13.9	911
12	Aspirin as an Antiplatelet Drug. New England Journal of Medicine, 1994, 330, 1287-1294.	13.9	894
13	Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects. Journal of Clinical Investigation, 1982, 69, 1366-1372.	3.9	854
14	In Vivo Formation of 8-Iso-Prostaglandin F _{2Î±} and Platelet Activation in Diabetes Mellitus. Circulation, 1999, 99, 224-229.	1.6	721
15	Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thrombosis Research, 1980, 17, 317-327.	0.8	644
16	Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. Journal of Clinical Oncology, 2005, 23, 2224-2232.	0.8	631
17	COVID-19 vaccines: where we stand and challenges ahead. Cell Death and Differentiation, 2021, 28, 626-639.	5.0	626
18	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. Chest, 2004, 126, 234S-264S.	0.4	578

#	Article	IF	Citations
19	Platelet-Active Drugs. Chest, 2001, 119, 39S-63S.	0.4	569
20	Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus. New England Journal of Medicine, 1990, 322, 1769-1774.	13.9	565
21	Platelet Activation in Obese Women. JAMA - Journal of the American Medical Association, 2002, 288, 2008.	3.8	484
22	Antiplatelet Drugs. Chest, 2008, 133, 199S-233S.	0.4	478
23	Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.. Circulation, 1983, 67, 1174-1177.	1.6	471
24	Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2309-2315.	1.1	437
25	Clinical pharmacology of platelet cyclooxygenase inhibition.. Circulation, 1985, 72, 1177-1184.	1.6	424
26	The role of aspirin in cancer prevention. Nature Reviews Clinical Oncology, 2012, 9, 259-267.	12.5	424
27	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 2005, 105, 2664-2670.	0.6	389
28	Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. Journal of Clinical Investigation, 2001, 108, 7-13.	3.9	361
29	In Vivo Formation of 8-Epi-Prostaglandin F _{2Î±} Is Increased in Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3230-3235.	1.1	356
30	Effects of Sulindac and Ibuprofen in Patients with Chronic Glomerular Disease. New England Journal of Medicine, 1984, 310, 279-283.	13.9	345
31	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. European Heart Journal, 2004, 25, 166-181.	1.0	334
32	Lipid Peroxidation in Diabetes Mellitus. Antioxidants and Redox Signaling, 2005, 7, 256-268.	2.5	303
33	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7634-7639.	3.3	295
34	Aspirin resistance: definition, mechanisms and clinical read-outs. Journal of Thrombosis and Haemostasis, 2003, 1, 1710-1713.	1.9	270
35	The clinical significance of inhibition of renal prostaglandin synthesis. Kidney International, 1987, 32, 1-12.	2.6	265
36	Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 247-251.	1.1	244

#	Article	IF	Citations
37	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology, 2009, 53, 667-677.	1.2	234
38	Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects. Circulation, 2004, 109, 1468-1471.	1.6	224
39	Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina. Circulation, 2000, 102, 1007-1013.	1.6	212
40	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to lowâ€dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 2012, 10, 1220-1230.	1.9	211
41	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. Circulation, 2017, 136, 1749-1764.	1.6	211
42	Estimated rate of thromboxane secretion into the circulation of normal humans.. Journal of Clinical Investigation, 1986, 77, 590-594.	3.9	211
43	Aspirin and Cancer. Journal of the American College of Cardiology, 2016, 68, 967-976.	1.2	209
44	Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 2011, 32, 2922-2932.	1.0	203
45	Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease. Circulation, 2002, 106, 2800-2805.	1.6	199
46	Evidence for a Direct Stimulatory Effect of Prostacyclin on Renin Release in Man. Journal of Clinical Investigation, 1982, 69, 231-239.	3.9	196
47	Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood, 2012, 119, 3595-3603.	0.6	187
48	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.. Journal of Clinical Investigation, 1985, 76, 1011-1018.	3.9	186
49	Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo. Circulation, 1997, 96, 69-75.	1.6	180
50	Platelet-Active Drugs. Chest, 1998, 114, 470S-488S.	0.4	177
51	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	1.0	175
52	Increased thromboxane biosynthesis in type IIa hypercholesterolemia.. Circulation, 1992, 85, 1792-1798.	1.6	174
53	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD â€“ Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	0.9	173
54	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 422-432.	1.2	169

#	Article	IF	Citations
55	Differential Effects of Aspirin and Non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women. Epidemiology, 2000, 11, 382-387.	1.2	169
56	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology and Hepatology, 2018, 3, 231-241.	3.7	156
57	Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT. Journal of Clinical Investigation, 1983, 71, 762-768.	3.9	153
58	Leukotrienes in the rat central nervous system.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 6212-6216.	3.3	151
59	Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.. Journal of Clinical Investigation, 1993, 92, 1400-1406.	3.9	141
60	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	1.2	140
61	Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 246-255.	1.1	135
62	Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina. Circulation, 1997, 96, 1109-1116.	1.6	133
63	Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus. Circulation, 2003, 107, 3199-3203.	1.6	131
64	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 2016, 7, 32462-32477.	0.8	130
65	Nutraceuticals in Diabetes and Metabolic Syndrome. Cardiovascular Therapeutics, 2010, 28, 216-226.	1.1	128
66	Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay. FEBS Letters, 1982, 146, 111-114.	1.3	120
67	Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. Journal of Clinical Investigation, 1999, 103, 1469-1477.	3.9	120
68	Oxidative Stress and Platelet Activation in Homozygous Homocystinuria. Circulation, 2001, 104, 1124-1128.	1.6	119
69	Improvement of Renal Function with Selective Thromboxane Antagonism in Lupus Nephritis. New England Journal of Medicine, 1989, 320, 421-425.	13.9	118
70	Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends in Pharmacological Sciences, 1989, 10, 453-458.	4.0	117
71	THE SYNOVIAL PROSTAGLANDIN SYSTEM IN CHRONIC INFLAMMATORY ARTHRITIS: DIFFERENTIAL EFFECTS OF STEROIDAL AND NONSTEROIDAL ANTIâ€INFLAMMATORY DRUGS. British Journal of Pharmacology, 1981, 73, 893-901.	2.7	116
72	Effects of intravenous prostacyclin in variant angina.. Circulation, 1982, 65, 470-477.	1.6	114

#	Article	IF	Citations
73	Insulin Resistance as a Determinant of Platelet Activation in Obese Women. Journal of the American College of Cardiology, 2006, 48, 2531-2538.	1.2	114
74	Drug Insight: aspirin resistanceâ€"fact or fashion?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 42-50.	3.3	111
75	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. Arthritis and Rheumatism, 2003, 48, 12-20.	6.7	110
76	Cardiovascular effects of cyclooxygenaseâ€2 inhibitors: a mechanistic and clinical perspective. British Journal of Clinical Pharmacology, 2016, 82, 957-964.	1.1	109
77	Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Analytical Biochemistry, 1986, 155, 198-205.	1.1	106
78	Effects of Vitamin E Supplementation on F ₂ -Isoprostane and Thromboxane Biosynthesis in Healthy Cigarette Smokers. Circulation, 2000, 102, 539-545.	1.6	106
79	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	1.0	106
80	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. Journal of the American College of Cardiology, 2015, 66, 74-85.	1.2	105
81	Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease. Thrombosis and Haemostasis, 1998, 79, 691-705.	1.8	104
82	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clinical Pharmacology and Therapeutics, 2006, 80, 264-274.	2.3	103
83	Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2006, 47, 391-397.	1.2	102
84	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood, 2010, 115, 1054-1061.	0.6	100
85	Nonsteroidal Anti-Inflammatory Drugs and the Heart. Circulation, 2014, 129, 907-916.	1.6	99
86	Radioimmunoassay measurement of prostaglandins E2 and F2Î± in human urine. Journal of Endocrinological Investigation, 1979, 2, 173-182.	1.8	98
87	Dissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable Angina. Thrombosis and Haemostasis, 1990, 63, 163-168.	1.8	98
88	Role of aspirin in primary prevention of cardiovascular disease. Nature Reviews Cardiology, 2019, 16, 675-686.	6.1	97
89	Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochimica Et Biophysica Acta - General Subjects, 1989, 992, 66-70.	1.1	95
90	Thromboxane synthesis and action within the kidney. Kidney International, 1992, 41, 1483-1493.	2.6	95

#	Article	IF	Citations
91	In VivoLipid Peroxidation and Platelet Activation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1195-1201.	2.5	91
92	Aspirin: Promise and Resistance in the New Millennium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s25-32.	1.1	91
93	Increased thromboxane biosynthesis in patients with acute cerebral ischemia.. Stroke, 1993, 24, 219-223.	1.0	89
94	Increased Thromboxane Biosynthesis in Essential Thrombocythemia. Thrombosis and Haemostasis, 1995, 74, 1225-1230.	1.8	88
95	Antiplatelet drugs. British Journal of Pharmacology, 2006, 147, S241-S251.	2.7	86
96	Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. Journal of the American College of Cardiology, 1993, 22, 283-290.	1.2	85
97	Determinants of F2-isoprostane biosynthesis and inhibition in man. Chemistry and Physics of Lipids, 2004, 128, 149-163.	1.5	85
98	Determinants of the interindividual variability in response to antiplatelet drugs. Journal of Thrombosis and Haemostasis, 2005, 3, 1597-1602.	1.9	84
99	Evidence for an extra-renal origin of urinary prostaglandin E2 in healthy men. Prostaglandins, 1979, 18, 623-629.	1.2	82
100	Role of prostaglandin F2 in human cerebral vasospasm. Journal of Neurosurgery, 1974, 41, 293-299.	0.9	80
101	Aspirin and Other Platelet-Active Drugs. Chest, 1995, 108, 247S-257S.	0.4	80
102	Determinants of Platelet Activation in Human Essential Hypertension. Hypertension, 2004, 43, 64-70.	1.3	80
103	Reappraisal of the clinical pharmacology of lowâ€dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. Journal of Thrombosis and Haemostasis, 2014, 12, 1320-1330.	1.9	79
104	Evidence for episodic platelet activation in acute ischemic stroke.. Stroke, 1994, 25, 278-281.	1.0	78
105	Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood, 2013, 121, 1701-1711.	0.6	78
106	Platelet Activation and Lipid Peroxidation in Patients With Acute Ischemic Stroke. Stroke, 1997, 28, 1557-1563.	1.0	78
107	Effects of the novel antiâ€inflammatory compounds, Nâ€[2â€(cyclohexyloxy)â€4â€nitrophenyl] methanesulphonamide (NSâ€398) and 5â€methanesulphonamidoâ€6â€(2, 4â€difluorothiophenyl)â€1â€indanone (Lâ€745,) Tj ETQq Journal of Pharmacology, 1995, 116, 2429-2434.	2.7	77
108	Induction of prostaglandin endoperoxide synthaseâ€2 in human monocytes associated with cycloâ€oxygenaseâ€dependent F₂â€isoprostane formation. British Journal of Pharmacology, 1996, 118, 1285-1293.	2.7	76

#	Article	IF	Citations
109	Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation.. Circulation, 1985, 71, 1113-1120.	1.6	75
110	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Reviews in Oncology/Hematology, 1995, 20, 203-222.	2.0	74
111	Determinants of platelet activation in Alzheimer's disease. Neurobiology of Aging, 2007, 28, 336-342.	1.5	74
112	Postprandial hyperglycemia is a determinant of platelet activation in early typeÂ2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2010, 8, 828-837.	1.9	74
113	Isoprostane formation and inhibition in atherothrombosis. Current Opinion in Pharmacology, 2005, 5, 198-203.	1.7	71
114	Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. European Heart Journal, 2013, 34, 3403-3411.	1.0	71
115	Characterization of furosemide-induced activation of the renal prostaglandin system. European Journal of Pharmacology, 1979, 60, 181-187.	1.7	70
116	Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. Acta Physiologica Scandinavica, 1983, 117, 203-211.	2.3	70
117	Nonsteroidal antiinflammatory drugs: Past, present and futureâ˜†. Pharmacological Research, 2009, 59, 285-289.	3.1	70
118	Aspirin in Ischemic Cerebrovascular Disease. Stroke, 1996, 27, 756-760.	1.0	70
119	Release of two vasodilators, adenosine and prostacyclin, from isolated rabbit hearts during controlled hypoxia.. Journal of Physiology, 1983, 340, 487-501.	1.3	67
120	Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2003, 1, 250-256.	1.9	67
121	Offâ€Pump Coronary Artery Bypass Grafting: 30ÂYears of Debate. Journal of the American Heart Association, 2018, 7, e009934.	1.6	67
122	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 2020, 136, 171-182.	0.6	65
123	Aspirin: new cardiovascular uses for an old drug. American Journal of Medicine, 2001, 110, S62-S65.	0.6	62
124	Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascular Pharmacology, 2016, 78, 1-9.	1.0	60
125	Aspirin, platelet inhibition and cancer prevention. Platelets, 2018, 29, 779-785.	1.1	58
126	Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 31-39.	3.4	58

#	Article	IF	Citations
127	Arterial Grafts for Coronary Bypass. Circulation, 2019, 140, 1273-1284.	1.6	56
128	Measurement of Thromboxane Biosynthesis in Health and Disease. Frontiers in Pharmacology, 2019, 10, 1244.	1.6	55
129	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovascular Research, 2021, 117, 2001-2015.	1.8	55
130	Mechanisms of Bleeding and Thrombosis in Myeloproliferative Disorders. Thrombosis and Haemostasis, 1997, 78, 617-621.	1.8	55
131	Increased Platelet Activation in the Chronic Phase After Cerebral Ischemia and Intracerebral Hemorrhage. Stroke, 1999, 30, 546-549.	1.0	54
132	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. Kidney International, 1987, 31, 1248-1256.	2.6	49
133	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*. Clinical Pharmacology and Therapeutics, 1998, 63, 672-681.	2.3	47
134	Coxibs, Traditional NSAIDs, and Cardiovascular Safety Postâ€PRECISION: What We Thought We Knew Then and What We Think We Know Now. Clinical Pharmacology and Therapeutics, 2017, 102, 238-245.	2.3	47
135	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862.	3.7	47
136	Proarrhythmic Activity of Intracoronary Endothelin in Dogs. Journal of Cardiovascular Pharmacology, 1991, 17, 1007-1014.	0.8	46
137	Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 391-402.	1.3	45
138	Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. European Heart Journal, 1985, 6, 409-417.	1.0	44
139	Physiologic variables affecting thromboxane B2 production in human whole blood. Thrombosis Research, 1985, 37, 1-8.	0.8	44
140	Platelet Activation and Inhibition in Unstable Coronary Syndromes. American Journal of Cardiology, 1997, 80, 17E-20E.	0.7	44
141	In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. Diabetes, 2016, 65, 503-509.	0.3	43
142	Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. FASEB Journal, 1989, 3, 1941-1948.	0.2	42
143	Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. American Journal of Medicine, 1986, 81, 71-83.	0.6	41
144	Lowâ€Dose Aspirin Acetylates Cyclooxygenaseâ€1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. Clinical Pharmacology and Therapeutics, 2017, 102, 52-61.	2.3	38

#	Article	IF	Citations
145	Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. Current Cardiology Reports, 2016, 18, 25.	1.3	36
146	In Vivo Platelet Activation in Diabetes Mellitus. Seminars in Thrombosis and Hemostasis, 1991, 17, 422-425.	1.5	35
147	Effects of nabumetone on prostanoid biosynthesis in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 335-341.	2.3	35
148	The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. Clinical Pharmacology and Therapeutics, 2001, 70, 475-483.	2.3	35
149	Effects of sulindac on renal and extrarenal eicosanoid synthesis. Clinical Pharmacology and Therapeutics, 1987, 41, 380-383.	2.3	34
150	Helicobacter Pylori Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 246-251.	1.1	33
151	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. American Journal of Cardiology, 1985, 55, 589-590.	0.7	32
152	Cigarette Smoking Knowledge and Perceptions Among Students in Four Italian Medical Schools. Nicotine and Tobacco Research, 2012, 14, 1065-1072.	1.4	32
153	Increased Thromboxane Biosynthesis Is Associated With Poststroke Dementia. Stroke, 1999, 30, 1542-1547.	1.0	31
154	Pulmonary formation of prostacyclin in man. Prostaglandins, 1981, 22, 323-332.	1.2	30
155	Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends in Cardiovascular Medicine, 1992, 2, 15-20.	2.3	30
156	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer Journal, 2018, 8, 49.	2.8	30
157	Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole Mood. European Journal of Pharmacology, 1990, 191, 83-88.	1.7	29
158	Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. Journal of the American College of Cardiology, 1993, 21, 1377-1381.	1.2	29
159	Cyclooxygenase-2 Polymorphism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1516-1518.	1.1	29
160	Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. European Journal of Pharmacology, 1989, 171, 127-134.	1.7	28
161	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney International, 1990, 38, 447-458.	2.6	28
162	Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. Journal of Immunological Methods, 1993, 162, 179-192.	0.6	28

#	Article	IF	Citations
163	Prevention of Myocardial Infarction and Stroke by Aspirin. Thrombosis Research, 1998, 92, S7-S12.	0.8	28
164	Type 2 Diabetes, Obesity, and Aspirin Responsiveness. Journal of the American College of Cardiology, 2017, 69, 613-615.	1.2	28
165	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?Sometimes earlier may not be betterBackground, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3316-3323.	1.0	26
166	Effects of Unfractionated and Low Molecular Weight Heparins on Platelet Thromboxane Biosynthesis â€œIn Vivoâ€• Thrombosis and Haemostasis, 1994, 72, 942-946.	1.8	26
167	Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney International, 1995, 47, 1168-1175.	2.6	24
168	The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine, 2010, 61, 49-61.	5.0	24
169	Aspirin and Other COX-1 Inhibitors. Handbook of Experimental Pharmacology, 2012, , 137-164.	0.9	24
170	Onâ€pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. Clinical Pharmacology and Therapeutics, 2017, 102, 849-858.	2.3	24
171	Aspirin for the prevention of coronary thrombosis: Current facts and perspectives. European Heart Journal, 1986, 7, 454-459.	1.0	23
172	Regulation of Endothelin-1 Biosynthesisa. Annals of the New York Academy of Sciences, 1994, 714, 109-121.	1.8	23
173	Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. Cancer Prevention Research, 2020, 13, 877-888.	0.7	23
174	Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes/metabolism Reviews, 1993, 9, 177-188.	0.2	22
175	The PGH-Synthase System and Isozyme-selective Inhibition. Journal of Cardiovascular Pharmacology, 2006, 47, S1-S6.	0.8	22
176	Release of prostaglandin F1Î± and F2Î± from superfused platelets: Quantitative evaluation of the inhibitory effects of some aspirin-like drugs. Prostaglandins, 1975, 9, 557-568.	1.2	21
177	Aspirin intolerance: Unaltered susceptibility of platelet cyclo-oxygenase to inhibition by aspirin in vitro. Journal of Allergy and Clinical Immunology, 1978, 62, 271-275.	1.5	21
178	Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and i.v. glucose. Acta Diabetologica Latina, 1974, 11, 330-339.	0.2	20
179	PLATELET AND VASCULAR ARACHIDONIC ACID METABOLITES: CAN THEY HELP DETECT A TENDENCY TOWARDS THROMBOSIS?*. British Journal of Haematology, 1984, 57, 209-212.	1.2	20
180	Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. Journal of Thrombosis and Haemostasis, 2010, 8, 914-22.	1.9	20

#	Article	IF	Citations
181	In Silico Modeling of the Antiplatelet Pharmacodynamics of Lowâ€dose Aspirin in Health and Disease. Clinical Pharmacology and Therapeutics, 2017, 102, 823-831.	2.3	20
182	In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thrombosis and Haemostasis, 2014, 112, 118-127.	1.8	19
183	Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1346-1349.	3.8	18
184	Aspirin for the Control of Platelet Activation and Prevention of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Current Insights and Rationale for Future Studies. Seminars in Thrombosis and Hemostasis, 2006, 32, 251-259.	1.5	18
185	The P2Y12 receptor: no active metabolite, no party. Nature Reviews Cardiology, 2009, 6, 271-272.	6.1	18
186	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e8-e14.	1.0	18
187	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodiumâ€“Induced Colitis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 416-426.	1.3	18
188	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. Diabetes Research and Clinical Practice, 2020, 160, 108008.	1.1	18
189	Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 Câ†'T polymorphism. Thrombosis and Haemostasis, 2012, 108, 533-542.	1.8	17
190	The involvement of arachidonic acid metabolism in the control of renin release. Journal of Endocrinological Investigation, 1980, 3, 193-201.	1.8	16
191	Prostacyclin does not affect insulin secretion in humans. Prostaglandins, 1981, 21, 379-385.	1.2	16
192	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2014, 35, 1824-1824.	1.0	16
193	Echinococcus granulosus: Evaluation of purified antigens' immunoreactivity. Experimental Parasitology, 1974, 35, 52-60.	0.5	15
194	Cardiac formation of prostacyclin during cardioplegia in man. Prostaglandins, 1982, 24, 5-19.	1.2	15
195	Leukotriene C4 stimulates LH secretion from rat pituitary cells in vitro. European Journal of Pharmacology, 1984, 106, 459-460.	1.7	15
196	Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. Biochimica Et Biophysica Acta - General Subjects, 1989, 992, 71-77.	1.1	15
197	Release of Contracting Autacoids by Aortae of Normal and Atherosclerotic Rabbits. Journal of Cardiovascular Pharmacology, 1992, 20, S208-S210.	0.8	15
198	GuÃa de prÃ¡ctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃ³n con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	0.6	15

#	Article	IF	Citations
199	Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thrombosis and Haemostasis, 2016, 116, 891-896.	1.8	15
200	COVID 19: in the eye of the cytokine storm. European Heart Journal, 2021, 42, 150-151.	1.0	15
201	Plasma and Synovial Fluid Pharmacokinetics and Prostaglandin Inhibitory Effect of Indoprofen in Patients with Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1980, 9, 123-126.	0.6	14
202	In vivo expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3923-3927.	3.3	14
203	In vivo thromboxaneâ€dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes/Metabolism Research and Reviews, 2020, 36, e3232.	1.7	14
204	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. Experimental Hematology, 2004, 32, 925-934.	0.2	13
205	Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. Prostaglandins, 1981, 22, 105-115.	1.2	12
206	Thromboxane synthesis inhibitors and receptor antagonists. Thrombosis Research, 1990, 57, 15-23.	0.8	12
207	Differential Effects of Leukotriene C4 on Endothelin-1 and Prostacyclin Release by Cultured Vascular Cells. Pharmacological Research, 1993, 27, 281-286.	3.1	12
208	Platelet progenitors: the hidden drug target. European Heart Journal, 2015, 36, 3211-3213.	1.0	12
209	Aspirin in Polycythemia Vera and Essential Thrombocythemia: Current Facts and Perspectives. Leukemia and Lymphoma, 1996, 22, 83-86.	0.6	11
210	Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e15-e21.	1.0	11
211	Selective COX-2 inhibitors: where do we go from here?. Lancet, The, 2008, 372, 1712-1713.	6.3	10
212	Knowledge about Health Effects of Cigarette Smoking and Quitting among Italian University Students: The Importance of Teaching Nicotine Dependence and Treatment in the Medical Curriculum. BioMed Research International, 2014, 2014, 1-9.	0.9	10
213	Evidence for a direct vasoconstrictor effect of big endothelin-1 in the rat kidney. European Journal of Pharmacology, 1992, 221, 267-273.	1.7	9
214	CardioPulse ArticlesWhat's new in the 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationâ€˜Ten Commandmentsâ€™ of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS)Quality measures in acute coronary syndromesCyclosporine to reduce myocardial infarction injury?Hearts in sightExercise and stop. European Heart Journal, 2016, 37, 206-216.	1.0	9
215	Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. Kidney International, 1995, 47, 106-113.	2.6	8
216	Role of Clinical Pharmacology in the Development of Antiplatelet Drugs. Clinical Therapeutics, 2014, 36, 2096-2111.	1.1	8

#	Article	IF	Citations
217	Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. European Heart Journal, 2020, 41, 4387-4388.	1.0	8
218	Heterologous in vivo processing of human preproendothelin 1 into bioactive peptides.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8939-8943.	3.3	7
219	Coxibs and traditional NSAIDs for pain relief â€“ Authors' reply. Lancet, The, 2014, 383, 122.	6.3	7
220	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. European Heart Journal, 2021, 42, 2814-2815.	1.0	7
221	Pharmacologic modulation of arachidonic acid metabolism in man. A minireview with emphasis on radioimmunological methods used to quantitate drug effects. International Journal of Immunopharmacology, 1982, 4, 127-133.	1.1	6
222	Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic Vascular Disease. Circulation, 2013, 128, 684-686.	1.6	6
223	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. Cardiovascular Research, 2017, 113, e61-e63.	1.8	6
224	The EMPEROR-Preserved study: end of the search for the â€œPhoenixâ€•or beginning of a new season for trials in heart failure with preserved ejection fraction. European Heart Journal, 2021, 42, 4621-4623.	1.0	6
225	Aspirin at 120: Retiring, recombining, or repurposing?. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12516.	1.0	6
226	Association of Platelet Thromboxane Inhibition by Lowâ€Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	2.3	6
227	Do pituitary prostaglandins play an essential role in the action of LH-RH in man?. Prostaglandins, 1974, 6, 345-348.	1.2	5
228	Characterization of Biochemical and Functional Effects of Antiplatelet Drugs as a Key to Their Clinical Development. Thrombosis and Haemostasis, 1995, 74, 396-400.	1.8	5
229	Tissueâ€selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. Clinical Physiology, 1984, 4, 443-447.	0.7	4
230	Inhibition of Renal Prostaglandin Synthesis in Man: Methodological and Clinical Implications. Scandinavian Journal of Rheumatology, 1986, 15, 14-25.	0.6	4
231	Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. Thrombosis Research, 1990, 60, 169-175.	0.8	4
232	Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 2016, 18, 48.	1.3	4
233	Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial. European Heart Journal, 2020, 41, 3880-3881.	1.0	4
234	Early rhythm control for early atrial fibrillation? Comment on the EAST-AFNET 4 Trial. European Heart Journal, 2020, 41, 3987-3988.	1.0	4

#	Article	IF	Citations
235	Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?. European Heart Journal, 2020, 41, 4232-4233.	1.0	4
236	PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. European Heart Journal, 2021, 42, 1130-1131.	1.0	4
237	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. European Heart Journal, 2021, 42, 1458-1459.	1.0	4
238	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. European Heart Journal, 2021, 42, 2329-2330.	1.0	4
239	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. European Heart Journal, 2021, 42, 370-371.	1.0	4
240	Platelet activation in unstable angina. , 1989, , 70-77.		4
241	Thromboxane Biosynthesis and Metabolism in Relation to Cardiovascular Risk Factors. , 1992, 37, 10-17.		4
242	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. European Heart Journal, 2021, 42, 14-15.	1.0	4
243	Increased risk of incident diabetes in patients with long COVID. European Heart Journal, 2022, 43, 2094-2095.	1.0	4
244	Less Thromboxane, Longer Life. Journal of the American College of Cardiology, 2022, 80, 251-255.	1.2	4
245	Thromboxane Biosynthesis and Pharmacologic Modulation in Progressive Glomerulosclerosis. American Journal of Nephrology, 1989, 9, 13-16.	1.4	3
246	[4] Radioimmunoassay of 11-dehydrothromboxane B2. Methods in Enzymology, 1990, 187, 34-42.	0.4	3
247	Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. Cardiovascular Research, 1997, 33, 295-296.	1.8	3
248	Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies. JAMA - Journal of the American Medical Association, 2008, 300, 900.	3.8	3
249	Aspirin for asymptomatic atherosclerosis?. Nature Reviews Cardiology, 2010, 7, 306-307.	6.1	3
250	El Ã¡cido acetilsalicÃ¡lico continÃºa siendo objeto de investigaciÃ³n y debate 115 aÃ±os despuÃ©s de su sÃntesis. Revista Espanola De Cardiologia, 2013, 66, 251-254.	0.6	3
251	Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. European Heart Journal, 2020, 41, 3882-3883.	1.0	3
252	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the â€˜Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19â€™. European Heart Journal, 2020, 41, 4389-4390.	1.0	3

#	Article	IF	Citations
253	Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI Trial. European Heart Journal, 2020, 41, 4301-4302.	1.0	3
254	Physical activity and mortality reduction: is volume or intensity the key variable?. European Heart Journal, 2021, 42, 730-731.	1.0	3
255	A SPRINT towards tighter control of blood pressure in hypertension. European Heart Journal, 2021, 42, 3042-3043.	1.0	3
256	Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism. European Heart Journal, 2021, 42, 4109-4110.	1.0	3
257	Nonsteroidal antiinflammatory drugs. , 2015, , 415-422.		3
258	The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. European Heart Journal, 2022, 43, 3016-3017.	1.0	3
259	Eicosanoid Biosynthesis and Metabolism in Myeloproliferative Disorders. Annals of the New York Academy of Sciences, 1994, 744, 229-236.	1.8	2
260	Role of Platelet Activation in Dementia. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 202-208.	0.5	2
261	Does aspirin increase the risk of major bleeds?. Nature Reviews Cardiology, 2012, 9, 495-496.	6.1	2
262	1068 Direct Evidence for Long-Lasting Acetylation of Cyclooxygenase-1 Associated With Reduction of Colorectal Mucosa Prostaglandin E2 Levels and Ribosomal Protein S6 Phosphorylation by Low-Dose Aspirin in Subjects Undergoing Colorectal Cancer Screening. Gastroenterology, 2016, 150, S211.	0.6	2
263	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e1-e7.	1.0	2
264	New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial. European Heart Journal, 2020, 41, 4089-4090.	1.0	2
265	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. European Heart Journal, 2020, 41, 3986-3987.	1.0	2
266	Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial. European Heart Journal, 2020, 41, 4166-4167.	1.0	2
267	Preventing a diabetes pandemic through lifestyle intervention. European Heart Journal, 2021, 42, 226-227.	1.0	2
268	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. European Heart Journal, 2021, 42, 561-562.	1.0	2
269	Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. European Heart Journal, 2021, 42, 882-883.	1.0	2
270	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. European Heart Journal, 2021, 42, 1061-1062.	1.0	2

#	Article	IF	Citations
271	When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. European Heart Journal, 2021, 42, 965-966.	1.0	2
272	StatinWISE sheds new light on statin-related muscle symptoms. European Heart Journal, 2021, 42, 1726-1727.	1.0	2
273	Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy?. European Heart Journal, 2021, 42, 2883-2884.	1.0	2
274	Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift?. European Heart Journal, 2021, 42, 4011-4012.	1.0	2
275	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. European Heart Journal, 2021, 42, 4518-4519.	1.0	2
276	Non-steroidal anti-inflammatory drugs. , 2011, , 485-493.		2
277	Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS1617-TPS1617.	0.8	2
278	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	2
279	Efficacy of a Mediterranean diet for the secondary prevention of cardiovascular disease. European Heart Journal, 0, , .	1.0	2
280	The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. European Heart Journal, 2020, 41, 4302-4303.	1.0	1
281	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on â€˜Dapagliflozin in Patients with Chronic Kidney Diseaseâ€™. European Heart Journal, 2020, 41, 4231-4232.	1.0	1
282	Iron heart. European Heart Journal, 2021, 42, 809-810.	1.0	1
283	Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. European Heart Journal, 2021, 42, 811-812.	1.0	1
284	Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?. European Heart Journal, 2021, 42, 2525-2526.	1.0	1
285	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. European Heart Journal, 2021, 42, 4211-4212.	1.0	1
286	Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?. European Heart Journal, 2021, 42, 4418-4419.	1.0	1
287	OUP accepted manuscript. European Heart Journal, 2021, 42, 4885-4886.	1.0	1
288	Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3318-3323.	1.0	1

#	Article	IF	Citations
289	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. European Heart Journal, 2022, 43, 448-449.	1.0	1
290	Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes. European Heart Journal, 2022, , .	1.0	1
291	Can targeting factor XIa dissociate thrombosis from haemostasis?. European Heart Journal, 2022, , .	1.0	1
292	Give genotype-guided dual antiplatelet therapy a second CHANCE. European Heart Journal, 2022, , .	1.0	1
293	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	1
294	A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. European Heart Journal, 2022, 43, 2354-2355.	1.0	1
295	Occurrence of Leukotrienes in Rat Brain. , 1985, , 17-26.		0
296	Renal Prostaglandins: Biochemistry and Functional Significance in Man. Contributions To Nephrology, 1989, 69, 55-66.	1.1	0
297	Authorsâ€™ response to â€œDrug Insight: aspirin resistanceâ€”fact or fashion?â€. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, E2-E2.	3.3	0
298	Prostanoids, Aspirin, and Related Compounds. , 2012, , 168-171.		0
299	Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis. Revista Espanola De Cardiologia (English Ed), 2013, 66, 251-254.	0.4	0
300	Gustav Born and life as â€œa series of ripples widening out from an original centreâ€. Platelets, 2018, 29, 761-762.	1.1	0
301	EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. European Heart Journal, 2020, 41, 3881-3882.	1.0	0
302	Out-of-Hospital Cardiac Arrest: Handle With Careâ€“Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. European Heart Journal, 2020, 41, 4165-4166.	1.0	0
303	Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?. European Heart Journal, 2021, 42, 1287-1288.	1.0	0
304	Vulnerable non-culprit coronary plaques: are they worth treating?. European Heart Journal, 2021, 42, 2233-2234.	1.0	0
305	Occluding to prevent occlusion. European Heart Journal, 2021, 42, 3224-3225.	1.0	0
306	Worsening of risk factor control in US diabetic patients: a call to action. European Heart Journal, 2021, 42, 3120-3121.	1.0	0

#	Article	IF	Citations
307	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. European Heart Journal, 2021, 42, 3902-3903.	1.0	0
308	First in man: gene editing for the treatment of transthyretin amyloidosis. European Heart Journal, 2021, 42, 3597-3598.	1.0	0
309	A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally. European Heart Journal, 2021, 43, 16-17.	1.0	0
310	Another STEP towards tighter control of blood pressure in the elderly. European Heart Journal, 2021, 42, 4715-4716.	1.0	0
311	Innovation in COX-2 Technology. Japanese Journal of Clinical Immunology, 2000, 23, 683-685.	0.0	0
312	The Effects of Low-Dose Aspirin and Selective Inhibitors of Thromboxane-Synthase on Eicosanoid Production in Man. , 1985, , 131-140.		0
313	Renal and Platelet Eicosanoids in Chronic Glomerular Disease. , 1989, , 121-136.		0
314	PlÃttchenaktivierung bei instabiler Angina pectoris. , 1989, , 76-84.		0
315	Featuring: Prof Carlo Patrono. European Cardiology Review, 2017, 12, 63.	0.7	0
316	The EHJ Weekly Journal Scan: Why? Who? How?. European Heart Journal, 2021, 42, 224-226.	1.0	0
317	Prostanoid Generation in Platelet Function. , 2005, , 267-281.		0
318	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. European Heart Journal, 2022, 43, 365-366.	1.0	0
319	Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19?. European Heart Journal, 2022, 43, 714-715.	1.0	0
320	Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs. European Heart Journal, 2022, , .	1.0	0
321	Differential cardiovascular effects of disease-modifying antirheumatic drugs in rheumatoid arthritis. European Heart Journal, 2022, , .	1.0	0
322	Placing the risk of myopericarditis following COVID-19 vaccination into perspective. European Heart Journal, 0, , .	1.0	0